The inhibitory effects of the bioactive components isolated from Scutellaria baicalensis on the cellular uptake mediated by the essential solute carrier transporters

Journal of Pharmaceutical Sciences

Volumn 102, Issue 11, 2013, Pages 4205-4211

  Xu, Fei ^a,b   Li, Zhen ^c   Zheng, Jian ^c,d   Gee Cheung, Florence Shin ^c   Chan, Ting ^c   Zhu, Ling ^e   Zhuge, Hongxiang ^b   Zhou, Fanfan ^c  

^a Health Hospital   (China)

^b SOOCHOW UNIVERSITY   (China)

^c UNIVERSITY OF SYDNEY   (Australia)

^d NORTHEAST FORESTRY UNIVERSITY   (China)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Baicalein; Baicalin; Disposition; Drug interactions; Organic anion transporters; Organic anion transporting polypeptide transporters; Organic cation transporters; Scutellaria baicalensis; Solute carrier transporters; Wogonin

Indexed keywords

BAICALEIN; BAICALIN; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; ORGANIC ANION TRANSPORTER 4; WOGONIN;

ARTICLE; CHEMICAL STRUCTURE; HERB DRUG INTERACTION; HUMAN; HUMAN CELL; IC 50; INTESTINE; KIDNEY; LIVER; NUCLEOTIDE SEQUENCE; SCUTELLARIA BAICALENSIS; TISSUE DISTRIBUTION;

BAICALEIN; BAICALIN; DISPOSITION; DRUG INTERACTIONS; ORGANIC ANION TRANSPORTERS; ORGANIC ANION-TRANSPORTING POLYPEPTIDE TRANSPORTERS; ORGANIC CATION TRANSPORTERS; SCUTELLARIA BAICALENSIS; SOLUTE CARRIER TRANSPORTERS; WOGONIN;

BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE; FLAVANONES; FLAVONOIDS; HUMANS; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PLANT EXTRACTS; SCUTELLARIA BAICALENSIS;

EID: 84885850124     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23727     Document Type: Article

References (74)

1. Nishimura M, Naito S. 2008. Tissue-specific mRNA expression profiles of human solute carrier transporter superfamilies. Drug Metab Pharmacokinet 23(1):22-44.
2. Nishimura M, Naito S. 2005. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet 20(6):452-477.
3. DeGorter MK, Xia CQ, Yang JJ, Kim RB. 2012. Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol 52:249-273.
4. Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W, Leake BF, Tirona RG, Kim RB. 2007. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 81(3):362-370.
5. Lee W, Glaeser H, Smith LH, Roberts RL, Moeckel GW, Gervasini G, Leake BF, Kim RB. 2005. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): Implications for altered drug disposition and central nervous system drug entry. J Biol Chem 280(10):9610-9617.
6. Su Y, Zhang X, Sinko PJ. 2004. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm 1(1):49-56.
7. Zhou F, You G. 2007. Molecular insights into the structure-function relationship of organic anion transporters OATs. Pharm Res 24(1):28-36.
8. Fujita T, Urban TJ, Leabman MK, Fujita K, Giacomini KM. 2006. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci 95(1):25-36.
9. Inui KI, Masuda S, Saito H. 2000. Cellular and molecular aspects of drug transport in the kidney. Kidney Int 58(3):944-958.
10. Fahrmayr C, Fromm MF, Konig J. 2010. Hepatic OATP and OCT uptake transporters: Their role for drug-drug interactions and pharmacogenetic aspects. Drug Metab Rev 42(3):380-401.
11. Koenen A, Kroemer HK, Grube M, Meyer zu Schwabedissen HE. 2011. Current understanding of hepatic and intestinal OATP-mediated drug-drug interactions. Expert Rev Clin Pharmacol 4(6):729-742.
12. Roth M, Obaidat A, Hagenbuch B. 2012. OATPs, OATs and OCTs: The organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol 165(5):1260-1287.
13. Poirier A, Funk C, Lave T, Noe J. 2007. New strategies to address drug-drug interactions involving OATPs. Curr Opin Drug Discov Devel 10(1):74-83.
14. Kivisto KT, Niemi M. 2007. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res 24(2):239-247.
15. Badagnani I, Castro RA, Taylor TR, Brett CM, Huang CC, Stryke D, Kawamoto M, Johns SJ, Ferrin TE, Carlson EJ, Burchard EG, Giacomini KM. 2006. Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther 318(2):521-529.
16. Zhou F, Lee AC, Krafczyk K, Zhu L, Murray M. 2011. Protein kinase C regulates the internalization and function of the human organic anion transporting polypeptide 1A2. Br J Pharmacol 162(6):1380-1388.
17. Sai Y, Kaneko Y, Ito S, Mitsuoka K, Kato Y, Tamai I, Artursson P, Tsuji A. 2006. Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab Dispos 34(8):1423-1431.
18. Shirasaka Y, Suzuki K, Nakanishi T, Tamai I. 2010. Intestinal absorption of HMG-CoA reductase inhibitor pravastatin mediated by organic anion transporting polypeptide. Pharm Res 27(10):2141-2149.
19. Zhou F, Xu W, Tanaka K, You G. 2008. Comparison of the interaction of human organic anion transporter hOAT4 with PDZ proteins between kidney cells and placental cells. Pharm Res 25(2):475-480.
20. Han TK, Everett RS, Proctor WR, Ng CM, Costales CL, Brouwer KL, Thakker DR. 2013. Organic cation transporter 1 (OCT1/mOct1) is localized in the apical membrane of Caco-2 cell monolayers and enterocytes. Mol Pharmacol 84(2):182-189.
21. Urban TJ, Brown C, Castro RA, Shah N, Mercer R, Huang Y, Brett CM, Burchard EG, Giacomini KM. 2008. Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther 83(3):416-421.
22. Tamai I, Yabuuchi H, Nezu J, Sai Y, Oku A, Shimane M, Tsuji A. 1997. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS Lett 419(1):107-111.
23. Toh DS, Cheung FS, Murray M, Pern TK, Lee EJ, Zhou F. 2013. Functional analysis of novel variants in the organic cation/ergothioneine transporter 1 identified in Singapore populations. Mol Pharm May 28. [Epub ahead of print]
24. Meier Y, Eloranta JJ, Darimont J, Ismair MG, Hiller C, Fried M, Kullak-Ublick GA, Vavricka SR. 2007. Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab Dispos 35(4):590-594.
25. Bolger MB, Lukacova V, Woltosz WS. 2009. Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine. AAPS J 11(2):353-363.
26. Tamai I, Ohashi R, Nezu J, Yabuuchi H, Oku A, Shimane M, Sai Y, Tsuji A. 1998. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 273(32):20378-20382.
27. Toh DS, Murray M, Pern Tan K, Mulay V, Grewal T, Lee EJ, Zhou F. 2011. Functional analysis of pharmacogenetic variants of human organic cation/carnitine transporter 2 (hOCTN2) identified in Singaporean populations. Biochem Pharmacol 82(11):1692-1699.
28. Jonker JW, Schinkel AH. 2004. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther 308(1):2-9.
29. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. 2002. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 302(2):510-515.
30. Meyer Zu Schwabedissen HE, Bottcher K, Chaudhry A, Kroemer HK, Schuetz EG, Kim RB. 2010. Liver X receptor alpha and farnesoid X receptor are major transcriptional regulators of OATP1B1. Hepatology 52(5):1797-1807.
31. van de Steeg E, Stranecky V, Hartmannova H, Noskova L, Hrebicek M, Wagenaar E, van Esch A, de Waart DR, Oude Elferink RP, Kenworthy KE, Sticova E, al-Edreesi M, Knisely AS, Kmoch S, Jirsa M, Schinkel AH. 2012. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest 122(2):519-528.
32. Uwai Y, Okuda M, Takami K, Hashimoto Y, Inui K. 1998. Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS Lett 438(3):321-324.
33. Kojima R, Sekine T, Kawachi M, Cha SH, Suzuki Y, Endou H. 2002. Immunolocalization of multispecific organic anion transporters, OAT1, OAT2, and OAT3, in rat kidney. J Am Soc Nephrol 13(4):848-857.
34. Gallegos TF, Martovetsky G, Kouznetsova V, Bush KT, Nigam SK. 2012. Organic anion and cation SLC22 "drug" transporter (Oat1, Oat3, and Oct1) regulation during development and maturation of the kidney proximal tubule. PLoS One 7(7):e40796.
35. Nozaki Y, Kusuhara H, Kondo T, Hasegawa M, Shiroyanagi Y, Nakazawa H, Okano T, Sugiyama Y. 2007. Characterization of the uptake of organic anion transporter (OAT) 1 and OAT3 substrates by human kidney slices. J Pharmacol Exp Ther 321(1):362-369.
36. Smith NF, Figg WD, Sparreboom A. 2005. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol 1(3):429-445.
37. Kobayashi Y, Sakai R, Ohshiro N, Ohbayashi M, Kohyama N, Yamamoto T. 2005. Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos 33(5):619-622.
38. Rizwan AN, Burckhardt G. 2007. Organic anion transporters of the SLC22 family: Biopharmaceutical, physiological, and pathological roles. Pharm Res 24(3):450-470.
39. Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, Zanger UM, Keppler D, Schwab M, Schaeffeler E. 2009. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 50(4):1227-1240.
40. Ishiguro N, Saito A, Yokoyama K, Morikawa M, Igarashi T, Tamai I. 2005. Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. Drug Metab Dispos 33(4):495-499.
41. Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, Ganapathy V. 2000. Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol 279(3):F449-F458.
42. Estudante M, Morais JG, Soveral G, Benet LZ. 2013. Intestinal drug transporters: An overview. Adv Drug Deliv Rev.Oct 4 [Epub ahead of print]
43. Shang X, He X, Li M, Zhang R, Fan P, Zhang Q, Jia Z. 2010. The genus Scutellaria an ethnopharmacological and phytochemical review. J Ethnopharmacol 128(2):279-313.
44. Li-Weber M. 2009. New therapeutic aspects of flavones: The anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treat Rev 35(1):57-68.
45. Chung H, Jung YM, Shin DH, Lee JY, Oh MY, Kim HJ, Jang KS, Jeon SJ, Son KH, Kong G. 2008. Anticancer effects of wogonin in both estrogen receptor-positive and -negative human breast cancer cell lines in vitro and in nude mice xenografts. Int J Cancer 122(4):816-822.
46. Ikemoto S, Sugimura K, Yoshida N, Yasumoto R, Wada S, Yamamoto K, Kishimoto T. 2000. Antitumor effects of Scutellariae radix and its components baicalein, baicalin, and wogonin on bladder cancer cell lines. Urology 55(6):951-955.
47. Kim SJ, Kim HJ, Kim HR, Lee SH, Cho SD, Choi CS, Nam JS, Jung JY. 2012. Antitumor actions of baicalein and wogonin in HT-29 human colorectal cancer cells. Mol Med Report 6(6):1443-1449.
48. Zhou QM, Wang S, Zhang H, Lu YY, Wang XF, Motoo Y, Su SB. 2009. The combination of baicalin and baicalein enhances apoptosis via the ERK/p38 MAPK pathway in human breast cancer cells. Acta Pharmacol Sin 30(12):1648-1658.
49. Xing J, Chen X, Sun Y, Luan Y, Zhong D. 2005. Interaction of baicalin and baicalein with antibiotics in the gastrointestinal tract. J Pharm Pharmacol 57(6):743-750.
50. Fan L, Zhang W, Guo D, Tan ZR, Xu P, Li Q, Liu YZ, Zhang L, He TY, Hu DL, Wang D, Zhou HH. 2008. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. Clin Pharmacol Ther 83(3):471-476.
51. Zhou J, Qu F, Yu Y, Nan R. 2008. Whether co-administration of garlic has negative influence on Scutellaria baicalensis Georgi in treating models rats with pelvic inflammation? Afr J Tradit Complement Altern Med 6(1):103-108.
52. Shitara Y, Takeuchi K, Nagamatsu Y, Wada S, Sugiyama Y, Horie T. 2012. Long-lasting inhibitory effects of cyclosporin A, but not tacrolimus, on OATP1B1- and OATP1B3-mediated uptake. Drug Metab Pharmacokinet 27(4):368-378.
53. Lai MY, Hsiu SL, Hou YC, Tsai SY, Chao PD. 2004. Significant decrease of cyclosporine bioavailability in rats caused by a decoction of the roots of Scutellaria baicalensis. Planta Med 70(2):132-137.
54. Nishimura N, Naora K, Hirano H, Iwamoto K. 1999. A Chinese traditional medicine, sho-saiko-to (xiao-chaihu-tang), reduces the bioavailability of tolbutamide after oral administration in rats. Am J Chin Med 27(3-4):355-363.
55. Nishimura N, Naora K, Hirano H, Iwamoto K. 1998. Effects of Sho-saiko-to on the pharmacokinetics and pharmacodynamics of tolbutamide in rats. J Pharm Pharmacol 50(2):231-236.
56. Ohnishi N, Okada K, Yoshioka M, Kuroda K, Nagasawa K, Takara K, Yokoyama T. 2002. Studies on interactions between traditional herbal and western medicines. V. effects of Sho-saiko-to (Xiao-Cai-hu-Tang) on the pharmacokinetics of carbamazepine in rats. Biol Pharm Bull 25(11):1461-1466.
57. VanWert AL, Gionfriddo MR, Sweet DH. 2010. Organic anion transporters: Discovery, pharmacology, regulation and roles in pathophysiology. Biopharm Drug Dispos 31(1):1-71.
58. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB. 2006. Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics. Gastroenterology 130(6):1793-1806.
59. Zhang L, Li C, Lin G, Krajcsi P, Zuo Z. 2011. Hepatic metabolism and disposition of baicalein via the coupling of conjugation enzymes and transporters-in vitro and in vivo evidences. AAPS J 13(3):378-389.
60. Zhou F, Zhu L, Cui PH, Church WB, Murray M. 2010. Functional characterization of nonsynonymous single nucleotide polymorphisms in the human organic anion transporter 4 (hOAT4). Br J Pharmacol 159(2):419-427.
61. Ueo H, Motohashi H, Katsura T, Inui K. 2005. Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol 70(7):1104-1113.
62. Ugele B, Bahn A, Rex-Haffner M. 2008. Functional differences in steroid sulfate uptake of organic anion transporter 4 (OAT4) and organic anion transporting polypeptide 2B1 (OATP2B1) in human placenta. J Steroid Biochem Mol Biol 111(1-2):1-6.
63. Noe J, Portmann R, Brun ME, Funk C. 2007. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 35(8):1308-1314.
64. Kobayashi Y, Ohshiro N, Sakai R, Ohbayashi M, Kohyama N, Yamamoto T. 2005. Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol 57(5):573-578.
65. Race JE, Grassl SM, Williams WJ, Holtzman EJ. 1999. Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem Biophys Res Commun 255(2):508-514.
66. Hirano M, Maeda K, Shitara Y, Sugiyama Y. 2004. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311(1):139-146.
67. Amphoux A, Millan MJ, Cordi A, Bonisch H, Vialou V, Mannoury la Cour C, Dupuis DS, Giros B, Gautron S. 2010. Inhibitory and facilitory actions of isocyanine derivatives at human and rat organic cation transporters 1, 2 and 3: A comparison to human alpha 1- and alpha 2-adrenoceptor subtypes. Eur J Pharmacol 634(1-3):1-9.
68. Grundemann D, Harlfinger S, Golz S, Geerts A, Lazar A, Berkels R, Jung N, Rubbert A, Schomig E. 2005. Discovery of the ergothioneine transporter. Proc Natl Acad Sci USA 102(14):5256-5261.
69. Wang H, Chan YL, Li TL, Wu CJ. 2012. Improving cachectic symptoms and immune strength of tumour-bearing mice in chemotherapy by a combination of Scutellaria baicalensis and Qing-Shu-Yi-Qi-Tang. Eur J Cancer 48(7):1074-1084.
70. Shao ZH, Vanden Hoek TL, Li CQ, Schumacker PT, Becker LB, Chan KC, Qin Y, Yin JJ, Yuan CS. 2004. Synergistic effect of Scutellaria baicalensis and grape seed proanthocyanidins on scavenging reactive oxygen species in vitro. Am J Chin Med 32(1):89-95.
71. Zhang N, Van Crombruggen K, Holtappels G, Bachert C. 2012. A herbal composition of Scutellaria baicalensis and eleutherococcus senticosus shows potent anti-inflammatory effects in an ex vivo human mucosal tissue model. Evid Based Complement Alternat Med 2012:673145.
72. Tong L, Wan M, Zhang L, Zhu Y, Sun H, Bi K. 2012. Simultaneous determination of baicalin, wogonoside, baicalein, wogonin, oroxylin A and chrysin of Radix scutellariae extract in rat plasma by liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal 70:6-12.
73. Tian S, He G, Song J, Wang S, Xin W, Zhang D, Du G. 2012. Pharmacokinetic study of baicalein after oral administration in monkeys. Fitoterapia 83(3):532-540.
74. Li J, Chen F, Dong H, Gao S. 2011. Study on plasma concentration and bioavailability of wogonin in Beagle's dogs. Chin Herbal Med 3(2):144-149.